Nobivac FeLV 25 x 1 Dose

Nobivac® FeLV Manufacturer: Intervet/Merck Animal Health This treatment applies to Cats Feline Leukemia Vaccine Killed Virus For Veterinary Use In Cats Only THIMEROSAL FREE In The Absence Of A Veterinarian-client-patient Relationship, U.S. Federal Regulations Prohibit The Relabeling, Repackaging, Resale Or Redistribution Of The Individual Contents Of This Package. Nobivac® FeLV vaccine is recommended for the vaccination of healthy cats as an aid in the prevention of lymphoid tumors caused by, and diseases associated with, feline leukemia virus (FeLV) infection. Vaccination with this product prevents persistent viremia in cats exposed to virulent feline leukemia virus. Nobivac® FeLV vaccine contains a tissue culture derived feline leukemia virus, Subgroups A and B. The virus has been chemically inactivated and combined with a proprietary adjuvant designed to enhance the immune response. Dosage and Administration: Prior To Use, Warm The Nobivac® Felv To Room Temperature And Shake Well. Initial vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly at 9 weeks of age or older. Second vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination. Two doses are required for primary immunization. A 22 gauge needle is recommended for the vaccination of FeLV. Revaccinate every 2 years with a single dose. Following the advice of the American Veterinary Medical Association on Vaccination Principles, an appropriate revaccination program for individual animals should be made based upon veterinarian-client-patient relationships. Studies indicate that cats vaccinated with Nobivac® FeLV are protected against persistent FeLV viremia for at least two years after vaccination. Precautions: Store at 2° - 7°C. Do not freeze. Do not mix with other vaccines. Use new, non-chemically sterilized needles and syringes. Burn vaccine container and all unused contents. Warnings: Contains gentamicin and amphotericin B as preservatives. Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas. The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction. It is important to realize that certain conditions and events may cause some cats to be unable to develop or maintain an adequate immune response following vaccination. Prior exposure to the disease, or disease latency, are conditions in which vaccination will not alter the course of the disease. Therefore, diagnostic testing of all cats for FeLV antigen prior to vaccination is recommended. Also, vaccination with this product will not offer cross-protection against feline immunodeficiency virus (FIV), another feline retrovirus. It is important to advise the cat owner of these situations prior to vaccination. Intervet Inc., Omaha, NE 68103 USA U.S. Veterinary License No. 165A 1 800 224-5318 (USA) 1 888 306-0069 (Canada) © 1999, 2009 Intervet Inc. All rights reserved. Presentation: 25 x 1 Dose Nac No. 10470725 INTERVET INC., MERCK ANIMAL HEALTH 556 MORRIS AVE., SUMMIT, NJ, 07901 Telephone: 908-473-5552 Order Desk: 800-648-2118 Fax: 908-473-5560 Customer Service: 800-521-5767 This item is NON-RETURNABLE and NON-REFUNDABLE.